Navigation Links
Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
Date:9/3/2007

DETROIT, Aug. 22 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd., (Amex: CPD) announced today that the US Food and Drug Administration (FDA) has granted final approval for the Company's Abbreviated New Drug Application (ANDA) for Phentermine Hydrochloride Tablets USP, 37.5 mg (Phentermine HCl).

Phentermine HCl is indicated only as short-term monotherapy for the management of exogenous obesity. Our generic Phentermine HCl is the bioequivalent to Adipex-P(R), a registered trademark of TEVA Pharmaceuticals USA, Inc. According to IMS Data, for the twelve months ended June 2007, Phentermine HCl generic and brand products (Adipex-P(R)) combined had annual sales of approximately $34 million.

Daniel H. Movens, Caraco's Chief Executive Officer, said, "We are pleased to gain this approval from the FDA. Our focus continues to be working towards expanding our product line effectively, including products that are already available generically in the market that potentially can add measurable value. We plan to market this product to the generic pharmaceutical market immediately. This will bring our total product selection to 36 different products represented by 74 various strengths."

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures, markets and distributes generic and private-label pharmaceuticals to the nation's largest wholesalers, distributors, drugstore chains and managed care providers.

Safe Harbor: This news release contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward- looking statements. These risks and uncertainties are contained in the Corporation's filings with the Securities and Exchange Commission and include, but are not limited to: information of a preliminary nature that may be subject to adjustment, potentially not obtaining or delay in obtaining FDA approval for new products, governmental restrictions on the sale of certain products, development by competitors of new or superior products or cheaper products or new technology for the production of products, the entry into the market of new competitors, market and customer acceptance and demand for new pharmaceutical products, availability of raw materials, timing and success of product development and launches, dependence on few products generating majority of sales, product liability claims for which the Company may be inadequately insured, and other risks identified in this report and from time to time in our periodic reports and registration statements. These forward- looking statements represent our judgment as of the date of this report. We disclaim, however, any intent or obligation to update our forward-looking statements.


'/>"/>
SOURCE Caraco Pharmaceutical Laboratories, Ltd.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. South Africa Wins landmark case against pharmaceutical giants
2. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
3. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
4. Setting up a new pharmaceutical industry in India
5. Medicis Pharmaceutical company enters pediatric market
6. Supply of Radiopharmaceuticals Hampered by Attacks
7. Pharmaceutical companies are targeting patients
8. FDA approves Watson Pharmaceuticals Oxytrol patch
9. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
10. Indian Pharmaceutical Industries Stops Manufacturing And Sale Of Valdecoxib
11. Pharmaceutical industries grant for R&D to be monitored
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/18/2017)... ... July 19, 2017 , ... USHEALTH Group, Inc. has ... in the prestigious CEO World Awards®. The coveted annual CEO World Awards ... services, CEO case studies, corporate social responsibility, and milestones from every major industry ...
(Date:7/17/2017)... ... July 17, 2017 , ... In a ... during Pregnancy , studies take a closer look at maternal depression, its effects ... with one study showing newer medications may be safer choices. , The scientific ...
(Date:7/17/2017)... (PRWEB) , ... July 17, 2017 , ... McGraw Family ... Patient Care and Train Next Generation of Healthcare Clinicians , NORWALK, Connecticut – ... is continuing its legacy of investing in community health by pledging up to $3 ...
(Date:7/17/2017)... ... July 17, 2017 , ... Altec Products, ... DocLink Advanced Admin Training in Atlanta, Georgia. The four-day training session, ... will allow them to manage DocLink more efficiently and effectively. , Covering topics ...
(Date:7/17/2017)... ... 17, 2017 , ... Western University of Health Sciences has ... Education for the sixth consecutive year, and also made the Honor Roll for ... Lebanon, Oregon, was recognized in seven categories: Collaborative Governance, Compensation & Benefits, Job ...
Breaking Medicine News(10 mins):
(Date:6/30/2017)... , June 30, 2017  AVACEN Medical (AVACEN) announced the ... The research describes the use of its AVACEN Treatment Method ... suffering from fibromyalgia. ... AVACEN Medical ... characterized by chronic widespread pain. It affects approximately 200 to 400 million ...
(Date:6/27/2017)... , June 27, 2017  Therapix Biosciences Ltd. (Nasdaq: ... company specializing in the development of cannabinoid-based drugs, today ... Market Opening Bell in New York, NY ... of its initial public offering (IPO) of American Depository ... March 2017. Dr. Elran Haber, Ph.D., Chief ...
(Date:6/20/2017)... and LAGUNA HILLS, Calif. ... presentation of new data that validate the use of ... stratify patients with multiple myeloma (MM). In a poster ... European Hematology Association (EHA) in Madrid, Spain ... of MMprofiler for identifying high-risk elderly patients. ...
Breaking Medicine Technology: